• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清胃蛋白酶原水平预测胃癌发病率的最佳临界值:久山研究

Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.

作者信息

Shikata Kentaro, Ninomiya Toshiharu, Yonemoto Koji, Ikeda Fumie, Hata Jun, Doi Yasufumi, Fukuhara Masayo, Matsumoto Takayuki, Iida Mitsuo, Kitazono Takanari, Kiyohara Yutaka

机构信息

Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Scand J Gastroenterol. 2012 Jun;47(6):669-75. doi: 10.3109/00365521.2012.658855. Epub 2012 Mar 20.

DOI:10.3109/00365521.2012.658855
PMID:22428879
Abstract

BACKGROUND

Serum pepsinogen (sPG) levels have been established as a good marker of chronic atrophic gastritis and the sequential occurrence of gastric cancer. However, there have been few prospective investigations which investigated the predictive performance of sPG for future gastric cancer incidence.

SUBJECTS AND METHODS

We prospectively followed-up a total of 2446 community-dwelling Japanese aged ≥ 40 years for 10 years and used the Youden's index to determine the cutoff values of the pepsinogen I level and pepsinogen I/II ratio to accurately discriminate gastric cancer events. Predictive performance of sPG was assessed by ROC curve.

RESULTS

During the follow-up, 69 subjects developed gastric cancer. The most predictive sPG test criteria were determined to be a pepsinogen I level ≤ 59 ng/ml and pepsinogen I/II ratio ≤ 3.9. The sensitivity and specificity of these criteria to discriminate the actual occurrence of gastric cancer were 71.0% and 69.2%, respectively. The area under the ROC curve for gastric cancer occurrence increased significantly by adding the sPG test to the model that included the status of Helicobater pylori infection and other potential risk factors (from 0.742 to 0.809; p for difference in the area < 0.001).

CONCLUSIONS

This study determined the optimal sPG test criteria for predicting gastric cancer occurrence over 10 years in a general Japanese population. These criteria would be effective to screen for individuals at high risk of this disease.

摘要

背景

血清胃蛋白酶原(sPG)水平已被确立为慢性萎缩性胃炎及胃癌相继发生的良好标志物。然而,很少有前瞻性研究调查sPG对未来胃癌发病率的预测性能。

对象与方法

我们对总共2446名年龄≥40岁的日本社区居民进行了为期10年的前瞻性随访,并使用约登指数来确定胃蛋白酶原I水平和胃蛋白酶原I/II比值的临界值,以准确区分胃癌事件。通过ROC曲线评估sPG的预测性能。

结果

在随访期间,69名受试者患上了胃癌。最具预测性的sPG检测标准被确定为胃蛋白酶原I水平≤59 ng/ml和胃蛋白酶原I/II比值≤3.9。这些标准区分实际发生的胃癌的敏感性和特异性分别为71.0%和69.2%。通过将sPG检测添加到包含幽门螺杆菌感染状况和其他潜在风险因素的模型中,胃癌发生的ROC曲线下面积显著增加(从0.742增加到0.809;面积差异的p值<0.001)。

结论

本研究确定了在一般日本人群中预测10年内胃癌发生的最佳sPG检测标准。这些标准将有效地筛查出该疾病的高危个体。

相似文献

1
Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.血清胃蛋白酶原水平预测胃癌发病率的最佳临界值:久山研究
Scand J Gastroenterol. 2012 Jun;47(6):669-75. doi: 10.3109/00365521.2012.658855. Epub 2012 Mar 20.
2
Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.通过血清胃蛋白酶原检测确定的癌症高危人群:无症状中年男性10年随访结果
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):838-45. doi: 10.1158/1055-9965.EPI-07-2762.
3
Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.在幽门螺杆菌感染流行的胃癌低发地区,利用胃蛋白酶原I、胃蛋白酶原II和胃泌素-17水平对胃肠化生和萎缩进行血清学评估。
Trop Gastroenterol. 2011 Oct-Dec;32(4):292-8.
4
Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach.各种胃部疾病中的血清胃蛋白酶原I和II水平,特别提及它们作为胃癌筛查试验的用途。
Trop Gastroenterol. 2007 Oct-Dec;28(4):166-70.
5
[Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].[智利人群中通过胃蛋白酶原血清水平检测胃肿瘤前病变]
Rev Med Chil. 2007 Dec;135(12):1519-25. Epub 2008 Feb 13.
6
[Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].[血清胃蛋白酶原异常用于筛查慢性萎缩性胃炎和胃癌的界值研究]
Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Oct;27(10):840-4.
7
Serum pepsinogen test for early detection of gastric cancer in a European country.在欧洲国家,血清胃蛋白酶原检测用于胃癌的早期发现。
Eur J Gastroenterol Hepatol. 2012 Jan;24(1):37-41. doi: 10.1097/MEG.0b013e32834d0a0a.
8
[Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].[胃癌高发区居民血清胃蛋白酶原水平与胃黏膜变化的相关性]
Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):507-11.
9
Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.抗壁细胞抗体和血清胃蛋白酶原检测在胃癌筛查中的应用
Dig Liver Dis. 2006 May;38(5):303-7. doi: 10.1016/j.dld.2005.10.021. Epub 2006 Mar 20.
10
[Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].[血清胃蛋白酶原I、II及骨桥蛋白联合检测在胃癌筛查中的评估]
Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):691-3.

引用本文的文献

1
Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.血清胃蛋白酶原作为美国胃癌的生物标志物:一项使用 PLCO 癌症筛查试验数据的巢式病例对照研究。
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1426-1432. doi: 10.1158/1055-9965.EPI-21-1328.
2
Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives.胃腺癌的新型生物标志物:当前研究与未来展望
Cancers (Basel). 2021 Nov 12;13(22):5660. doi: 10.3390/cancers13225660.
3
Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years.
为期七年的前瞻性研究中癌前萎缩性胃炎的筛查、监测与治疗
Asian Pac J Cancer Prev. 2020 Feb 1;21(2):331-336. doi: 10.31557/APJCP.2020.21.2.331.
4
The Value of Pepsinogen in GC Screening: A Systematic Review and Meta-Analysis.胃蛋白酶原在胃癌筛查中的价值:一项系统评价与Meta分析
Gastroenterol Res Pract. 2019 Jan 21;2019:7087232. doi: 10.1155/2019/7087232. eCollection 2019.
5
The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research.血清胃蛋白酶原在中国健康体检人群中诊断萎缩性胃炎的潜在价值:一项诊断性临床研究
BMC Gastroenterol. 2017 Jul 20;17(1):88. doi: 10.1186/s12876-017-0641-6.
6
Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.幽门螺杆菌抗体与血清胃蛋白酶原联合作为胃癌发病率的良好预测工具:来自久山研究的20年前瞻性数据
J Epidemiol. 2016 Dec 5;26(12):629-636. doi: 10.2188/jea.JE20150258. Epub 2016 Jun 4.
7
Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.血清胃蛋白酶原作为胃癌和萎缩性胃炎筛查生物标志物的意义:一项系统评价和荟萃分析
PLoS One. 2015 Nov 10;10(11):e0142080. doi: 10.1371/journal.pone.0142080. eCollection 2015.
8
Diagnosis of Helicobacter pylori infection: Current options and developments.幽门螺杆菌感染的诊断:当前的选择与进展
World J Gastroenterol. 2015 Oct 28;21(40):11221-35. doi: 10.3748/wjg.v21.i40.11221.
9
Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.新生物标志物和内镜技术时代的胃腺癌筛查与预防:一项成本效益分析
Gut. 2016 Apr;65(4):563-74. doi: 10.1136/gutjnl-2014-308588. Epub 2015 Mar 16.
10
Short term micronutrient-antioxidant supplementation has no impact on a serological marker of gastric atrophy in Zambian adults: retrospective analysis of a randomised controlled trial.短期微量营养素-抗氧化剂补充对赞比亚成年人胃萎缩血清学标志物无影响:一项随机对照试验的回顾性分析
BMC Gastroenterol. 2014 Mar 25;14:52. doi: 10.1186/1471-230X-14-52.